

## Research Article

# Correlation of sonographic prostate volume with international prostate symptom score in South Indian men

Basawaraj NG<sup>1\*</sup>, T. Arul Dasan<sup>2</sup>, Savitha S Patil<sup>3</sup>

<sup>1</sup>Department of Radio-Diagnosis, BGS Global Institute of Medical Sciences & Hospital, Bangalore, Karnataka, India

<sup>2</sup>Department of Radio-Diagnosis, BMC&RI, Bangalore, Karnataka, India

<sup>3</sup>Department of Community medicine, BGS Global Institute of Medical Sciences & Hospital, Bangalore, Karnataka, India

**Received:** 02 September 2015

**Accepted:** 06 October 2015

### \*Correspondence:

Dr. Basawaraj NG,

E-mail: basawarajng@gmail.com.

**Copyright:** © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

## ABSTRACT

**Background:** Benign prostatic hyperplasia (BPH) is a common disease in old age individuals, usually starts around the age of 40 years, the prevalence of benign prostatic hyperplasia rises to more than 50% at 50 years of age to as much as 90% at the age of 85 years. Proven BPH patients suffer from moderate to severe lower urinary tract symptoms (LUTS) that are symptoms related to storage and voiding of urine. This study was to determine relationship between sonologically measured prostate Volume and international prostate symptom score (IPSS).

**Methods:** Clinically symptomatic 126 patients in the age group of 40-89 years were studied. All the patients underwent Transabdominal sonography for the estimation of prostate volume and clinical questionnaire for international prostate symptom score. Statistical Analysis by descriptive and analytical statistics using SPSS version 16. Chi-Square test used and P values  $\leq 0.05$  was considered to be statistically significant.

**Results:** Among 126 individuals, The maximum number of patients, that is 45 patients had the prostate volume measuring 31-50 cc (35.7%), followed by 25 patients (19.8%) had the volume measuring more than 50 cc. Maximum number of patients 52 (41.3%) were having severe symptoms, 47 (37.3%) patients were having moderate symptoms and 27 patients symptoms and 27 patients (21.4%) were having mild symptoms. Prostate volume had statistically significant but weak correlation observed with IPSS ( $r=0.40$ ,  $p=0.001$ ), Weak Stream ( $r=0.31$ ,  $p=0.001$ ) and urgency ( $r=0.31$ ,  $p=0.001$ ).

**Conclusions:** Prostate volume had statistically significant but weak correlation observed with IPSS.

**Keywords:** Prostate volume, Prostate ultrasonography, Benign prostatic hyperplasia, International prostate symptom score

## INTRODUCTION

Benign prostatic hyperplasia (BPH) can be defined as documentable gross or histologic growth of prostate glandular tissues, stromal tissues, or both. Usually beginning around the age of 40 years, the prevalence of benign prostatic hyperplasia rises to more than 50% at 50 years of age to as much as 90% at the age of 85 years. As life expectancy increases, benign prostatic hyperplasia

will be a significant cause of morbidity. About 50% of men with histologically proven BPH have moderate to severe lower urinary tract symptoms (LUTS) that are symptoms related to storage and voiding of urine.<sup>1</sup>

The severity of lower urinary tract symptoms can be estimated by the International Prostate Symptoms Score (IPSS). This scoring system uses a seven point questionnaire with maximum total attainable score of 35

to assess baseline patient discomfort. IPSS is also a useful tool for follow up of patient's symptoms over time.<sup>2</sup>

The measurement of prostatic volume by ultrasonography is a readily available method that can be undertaken to aid decision making. Trans abdominal sonography is easy to perform, and provides reliable measurements of prostate size and its intravesical extension, post-void residual volume, also allowing simultaneous assessment of bladder and upper urinary tract.<sup>3</sup>

Prostatic volume is an important determinant for selecting the treatment, with surgeons preferring open resection for larger prostatic volumes.<sup>1</sup> The purpose of the present study is to determine the relation between sonographically determined prostate volumes and International Prostate Symptoms Score.

## METHODS

The present study was a prospective cohort observational study. The study was approved by Institute Ethical Committee and procedures followed in this study are in accordance with the ethical standard laid down by ICMR's ethical guidelines for biomedical research on human subjects (2006). A written informed consent was obtained from all the patients who participated in the study after explaining the patient's diagnosis, the nature and purpose of the study.

There were 126 individuals in the age group of 40-89 years (mean age of 65.06 years) with lower urinary tract symptoms. All the patients underwent Transabdominal sonography for the estimation of prostate volume and basic laboratory investigation including prostate specific antigen levels in blood. The patients with proven prostatic carcinoma, serum Prostate Specific Antigen levels above 10 ng/ml. and who have undergone previous prostatic surgery were excluded from the study. The International prostate symptom

Score (IPSS) was obtained by clinical questionnaire and personnel interview with the patient, prior to treatment on the following symptoms which they experienced over the past one month. 1) Incomplete emptying 2) Frequency 3) Intermittency 4) Urgency 5) Weak stream 6) Straining 7) nocturia 8) Bothersome score and Quality of life due to urinary symptoms.

The prostate gland was evaluated trans abdominally after adequate bladder distension. The prostate gland assessed for volume, echo texture, morphology, focal lesions and median lobe parenchymal calcification.. Parenchymal Calcifications The prostate volume was calculated by using Prolate ellipsoid formula Antero-posterior x Transverse x Cranio-caudal x 0.52. The grading of the prostate gland enlargement was done as follows<sup>4</sup> Grade – I- 21 – 30 cc. Grade – II - 31 – 50 cc Grade – III – 51 – 80 cc and Grade – IV – 80 cc and above. The median lobe enlargement was measured separately by obtaining


both in longitudinal and transverse planes. The median lobe volume was added to the total prostatic gland volume. The urinary bladder was assessed for various abnormalities like prevoid urine volume, wall thickness, mucosal regularity, calculi, diverticuli, tumor and post void assessment for the residual urine.

## Statistical analysis:


Statistical analyses were performed by statistics software; SPSS 16 (Chicago, USA). Descriptive statistics was used to provide an overview of sociodemographic profile of the study population. Chi-Square / Fisher exact test was employed to estimate the association between two variables. Spearman correlation coefficient for categorical data and Pearson's correlation coefficient analysis for continuous variables was carried out to assess correlation between prostate volume and other variables. P values  $\leq 0.05$  was considered to be statistically significant for all tests.

## RESULTS


The mean age of patients was  $65.06 \pm 9.06$  years and the age ranged from 40 to 89 years with interquartile range - 58, 65, 72. The maximum number of patients in the sixth decade constituted 35.7% followed by 31.7% of patients in seventh decade.




**Figure 1: Correlation between age and prostate volume.**



**Figure 2: Mean frequency of presentation of clinical features.**



**Figure 3: The correlation between prostate volume and International prostate symptom score (IPSS).**



**Figure 4: Prostatomegaly with enlarged median lobe in a 72 years old patient.**

**Table 1: Correlation of IPSS with age.**

Sr no.	Grading the severity of symptoms (IPSS)	Age in years					Total
		40-49	50-59	60-69	70-79	80-89	
1	Mild	1(3.8)	10(37.0)	10(37.0)	6(22.2)	0	27(21.4)
2	Moderate	3(6.4)	9(19.2)	17(36.1)	15(32.0)	3(6.3)	47(37.3)
3	Severe	1(2.0)	13(25.0)	18(34.5)	19(36.5)	1(2.0)	52(41.3)
4	Total	5(3.9)	32(25.4)	45(35.8)	40(31.8)	4(3.1)	126
p=0.51, r=0.11, p=0.21							

**Table 2: Correlation of IPSS with prostate volume (PV).**

Sr no.	Prostate volume	IPSS Grading			Total, n(%)
		Mild n(%)	Moderate n(%)	Severe n(%)	
1	≤ 20	9(53.0)	4(23.5)	4(23.5)	17(13.4)
2	21-30	11(28.2)	16(41.0)	12(30.8)	39(30.9)
3	31-50	7(15.5)	22(48.9)	16(35.6)	45(35.7)
4	51-80	0	3(14.2)	18(85.8)	21(16.6)
5	≥ 81	0	2(50.0)	2(50.0)	4(3.1)
p=0.001, r=0.40		27(21.4)	47(37.3)	52(41.3)	126

**Table 3: Correlation of prostate volume with various factors.**

SI No.	Factors	Mean	Standard Deviation	Pearson's Correlation Coefficient	P Value
	Prostate volume	36.35	16.06		
1	Age	65.06	9.02	0.19	0.03
2	Incomplete Emptying (IE)	2.07	2.24	0.27	0.002
3	Urgency	3.16	1.98	0.31	0.001
4	Nocturia	3.44	1.76	0.17	0.056
5	Frequency	3.41	1.89	0.28	0.002
6	Straining	1.94	2.18	0.20	0.025
7	Weak Stream	2.51	2.28	0.31	0.001
8	Intermittency	1.96	2.25	0.26	0.003
9	Quality of Life	4.44	3.26	0.27	0.002
10	IPSS	18.30	10.08	0.40	0.001

Maximum number of patients 52 (41.3%) were having severe symptoms, 47(37.3%) patients were having moderate symptoms and 27 patients (21.4%) were having mild symptoms. Statistically there was no significant association and no correlation between age and severity

of symptoms ( $p \geq 0.05$ ) (Table 1) which is also represented in Fig 1.

The commonest clinical presentation was nocturia in 118 patients (93.6%) followed by increased frequency of micturition in 105 patients (83.3%), Urgency in 97

(76.9%) of the patients, Incomplete emptying and Straining in 63(50%) of the patients. The median lobe enlargement was observed in 5 of the patients (3.9%) and international prostate symptoms score (IPSS) in these patients was 18.30. The mean values of the above clinical features are presented in Fig. 2. Statistically there is no significant correlation between median lobe enlargement and IPSS with  $p$  value  $\geq 0.05$  (0.25),  $r=0.10$ .

The maximum number of patients, that is 45 patients had the prostate volume measuring 31-50 cc (35.7%), followed by 25 patients (19.8%) had the volume measuring more than 50 cc. The lowest prostate volume was 10 cc and the largest prostate was 91 cc, mean being  $36.98 \text{ cc} \pm 18.05$ , with interquartile range 25, 33, 47 having median value of 33 cc. There is linear relationship between these variables i.e. prostate volume and IPSS ( $P = 0.001$ ). A positive weak correlation was found between PV and IPSS grading (Table 2) which is also depicted in fig 3. There was statistically significant but no correlation found between the prostate volume (PV) with age ( $r=0.19$ ,  $p=0.03$ ), incomplete emptying ( $r=0.27$ ,  $p=0.002$ ), frequency ( $r=0.28$ ,  $p=0.002$ ), straining ( $r=0.20$ ,  $p=0.02$ ), intermittency ( $r=0.26$ ,  $p=0.003$ ) quality of life ( $r=0.28$ ,  $p=0.002$ ) and nocturia ( $r=0.17$ ,  $p=0.056$ ). Prostate volume had statistically significant but with weak correlation observed with IPSS ( $r=0.40$ ,  $p=0.001$ ), Weak Stream ( $r=0.31$ ,  $p=0.001$ ) and urgency ( $r=0.31$ ,  $p=0.001$ ) (Table 3).

## DISCUSSION

Benign prostatic hyperplasia (BPH) is a cause of increased morbidity and burden in ageing men due to frequently associated lower urinary tract symptoms (LUTS), the LUTS may impair quality of life. BPH is also a progressive disease, mainly characterized by a deterioration of LUTS over time<sup>5</sup> It is better to assess the severity of symptoms rather than the increase in the prostatic volume in the management of BPH<sup>6</sup> Both American urology association and European urology association practice guideline agree to use the international prostate symptom score (IPSS) to evaluate severity of BPH.<sup>7</sup> It is translated and linguistically validated in many languages to use as universal tool for researchers around the world The IPSS is widely used to assess the severity of lower urinary tract symptoms in older men with features of bladder outlet obstruction. The IPSS in combination with uroflowmetry is used to guide treatment decisions, whether to manage medically or surgically. The IPSS is also used to evaluate therapeutic response in men with lower urinary tract symptoms. Ultrasonography of prostate is routinely done to assess prostate morphology, size, echo-pattern and median lobe enlargement. Trans abdominal ultrasonography helps not only in assessment of prostate but also urinary bladder, kidneys and ureters. Prevoid and postvoid residual urine can also be measured. The prostate volume, patient clinical symptoms and ultrasonography findings of

kidney, ureter and urinary bladder are vital in clinical decision making.

The mean age of patients in our study was  $65.06 \pm 9.06$  years which is almost similar with study by Sanjeev singla et. al. who had mean age of 67.7 years.<sup>8</sup> Nocturia was a commonest bothersome symptom found in 70 % of patients in a study by Mostafa et al.<sup>9</sup> In our study also nocturia was commonest bothersome symptom found in 93.6 % patients and it was main reason for the patients to seek medical help. Our study found a positive but weak correlation between prostate volume and IPSS grading, which is comparable to Overland Bet al. According to Overland Bet al positive modest correlation noted between IPSS and prostate volume.<sup>10</sup> Another study by Tsukamoto et al showed that a change in IPSS was associated with a change in prostate volume,<sup>11</sup> whereas study by Agrawal et al., Sanjeev singla et al, Udeh et al, and Ezz et al. showed no relationship between prostate size and IPSS score.<sup>6,8,12,13</sup> There was no correlation between the age and IPSS in our study, which is similar with Agrawal et al., but Bosch JL et al<sup>14</sup> states that very weak correlation between the IPSS and age ( $r = 0.09$ ,  $P = 0.04$ ). There is lot of variations in the findings by different authors, but most of studies found no strong correlation between the IPSS and prostate volume. The prostate volume alone is not useful in the estimation of disease severity,<sup>15</sup> patient symptomatology also to be considered.

## CONCLUSION

There is no correlation between the age and international prostate symptom score. The median lobe enlargement was not associated with significant increase in the international prostate symptom score. Nocturia was commonest bothersome symptom. No correlation found between the prostate volume with, incomplete emptying, frequency, straining intermittency, quality of life and nocturia. Prostate volume had statistically significant but weak correlation observed with total international prostate symptom score, weak stream and urgency.

*Funding: No funding sources*

*Conflict of interest: None declared*

*Ethical approval: Approved by ethics committee*

## REFERENCES

1. Wasserman NF. Benign Prostatic Hyperplasia: A review and ultrasound classification. The radiologic clinics of North America, Prostate gland. 2006;44:689-710.
2. American Urological Association. (2006) Guideline on the management of benign prostatic hyperplasia (BPH). American Urological Association. (Guideline Ref ID: AUA2006).
3. Garcia Navas R, SanzMayayo E, Arias Funez F. Diagnosis and follow up of benign prostatic

- hyperplasia by ultrasound. *Arch Esp Urol.* 2006;59:353-60.
4. Aguirre. Evaluation and comparison of prostate volume with open prostatectomy surgical specimen. *J. Urol.* 1980; 86:675-79.
5. Roehrborn CG. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. *BJU Int* 2008;101(3):17-21.
6. Agrawal CS, Chalise PR, Bhandari BB. Correlation of prostate volume with international prostate symptom score and quality of life in men with benign prostatic hyperplasia. *Nepal Med Coll J.* 2008;10(2):104-7.
7. Chuang FP, Lee SS, Wu ST, Yu DS, Chen HI, Chang SY, et al Change in International Prostate Symptom Score after transurethral prostatectomy in Taiwanese men with benign prostate hyperplasia: Use of these changes to predict the outcome. *Arch Androl* 2003;49:129-37.
8. Sanjeev Singla, Ramneesh Garg, Ankit Singla, Sandeep Sharma, Jasdeep Singh, Pulkit Sethi. Experience with uroflowmetry in evaluation of lower urinary tract symptoms in patients with benign prostatic hyperplasia. *Journal of Clinical and Diagnostic Research.* 2014;8(4):NC01-NC03.
9. Mostafa A. Arafa, Karim Farhat, Saad Aqdas, Mohamed Al-Atawi, Danny M. Rabah Assessment of lower urinary tract symptoms in Saudi men using the International Prostate Symptoms Score *Urol Ann.* 2015;7(2):221-5.
10. Overland GB, Vatten L, Rhodes T, DeMuro C, Jacobsen G, Vada K. Lower urinary tract symptoms, prostate volume and uroflow in norwegian community men. *Eur. Urol.* 2001;39(1):36-41.
11. Tsukamoto T, Masumori N, Rahman M, Crane MM. Change in International Prostate Symptom Score, prostate-specific antigen and prostate volume in patients with benign prostatic hyperplasia followed longitudinally. *Int J Urol.* 2007;14(4):321-4.
12. Udeh EI, Ozoemena OF, Ogwuche E. The relationship between prostate volume and international prostate symptom score in Africans with benign prostatic hyperplasia. *Niger J Med.* 2012;21(3):290-5.
13. Ezz El Din K, Kiemency LALM, de Wildt MJAM et al. Correlation between uroflowmetry, prostate volume, postvoid residue and lower urinary tract symptoms as measured by the international prostate symptoms score. *Urology* 1996;48: 393-7.
14. Bosch JL, Hop WC, Kirkels WJ, Schröder FH. The International Prostate Symptom Score in a community-based sample of men between 55 and 74 years of age: prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. *Br J Urol.* 1995;75(5):622-30.
15. Vesely S1, Knutson T, Damber JE, Dicuio M, Dahlstrand C. Relationship between age, prostate volume, prostate-specific antigen, symptom score and uroflowmetry in men with lower urinary tract symptoms. *Scand J Urol Nephrol.* 2003;37(4):322-8.

**Cite this article as:** Basawaraj NG, Dasan TA, Patil SS. Correlation of sonographic prostate volume with international prostate symptom score in South Indian men. *Int J Res Med Sci* 2015;3:3126-30.